Truist Securities has initiated coverage on Viridian Therapeutics Inc (VRDN) with a Buy rating as of November 23, 2025. The current price of VRDN stands at $32.03.
Viridian Therapeutics, headquartered in Waltham, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing proprietary RNA-targeted therapeutics. The firm is advancing multiple candidates for the treatment of thyroid eye disease (TED) and is conducting two global Phase 3 clinical trials, THRIVE and THRIVE-2, to assess the safety and efficacy of its leading candidate, veligrotug.
In addition to its TED portfolio, Viridian is developing a novel range of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which may have applications in various autoimmune diseases. The company has a market capitalization of $2.6 billion and reported an EPS (TTM) of -3.72.
Upcoming earnings are scheduled for August 4, 2026, with an estimated EPS of -1.11 and a revenue estimate of $25.6 million. Analyst consensus as of November 1, 2025, indicates a Buy rating, with 9 Strong Buy, 11 Buy, and 3 Hold ratings among 23 total assessments. Recent actions include Truist's initiation of coverage, alongside RBC Capital maintaining an Outperform rating and BTIG reiterating a Buy rating.
This update provides insight into the firm's strategic positioning as it continues to advance its pipeline in the competitive biotechnology sector.